Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review

Geoff Spurling and colleagues report findings of a systematic review looking at the relationship between exposure to promotional material from pharmaceutical companies and the quality, quantity, and cost of prescribing. They fail to find evidence of improvements in prescribing after exposure, and find some evidence of an association with higher prescribing frequency, higher costs, or lower prescribing quality.

[1]  S. Hauser,et al.  Marketing and drug costs: Who is laughing and crying? , 2007, Annals of neurology.

[2]  Sriram Venkataraman,et al.  The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..

[3]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[4]  J. Avorn,et al.  Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. , 1987, American journal of public health.

[5]  J P Gagnon,et al.  Effects of promotion on pharmaceutical demand. , 1985, Social science & medicine.

[6]  L Lasagna,et al.  Differential education concerning therapeutics and resultant physician prescribing patterns. , 1972, Journal of medical education.

[7]  Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care , 2005, Schizophrenia Research.

[8]  M. Sturkenboom,et al.  Determinants for the adoption of angiotensin II receptor blockers by general practitioners. , 2006, Social science & medicine.

[9]  Natalie Mizik,et al.  Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..

[10]  W P McKinney,et al.  Physicians, pharmaceutical sales representatives, and the cost of prescribing. , 1996, Archives of family medicine.

[11]  M. Ziegler,et al.  The accuracy of drug information from pharmaceutical sales representatives. , 1995, JAMA.

[12]  Pradeep K. Chintagunta,et al.  Strategic Pricing and Detailing Behavior in International Markets , 2005 .

[13]  M. Olfson,et al.  Adding or switching antipsychotic medications in treatment-refractory schizophrenia. , 2007, Psychiatric services.

[14]  E. Hemminki.  Content analysis of drug‐detailing by pharmaceutical representatives , 1977, Medical education.

[15]  S. Mcphee,et al.  Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. , 2001, The American journal of medicine.

[16]  Pradeep K. Chintagunta,et al.  Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis , 2004 .

[17]  F Haayer,et al.  Rational prescribing and sources of information. , 1982, Social science & medicine.

[18]  Richard E. Caves,et al.  Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals , 1988, The Journal of Law and Economics.

[19]  D. Berings,et al.  The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice , 2004, European Journal of Clinical Pharmacology.

[20]  N. Freemantle,et al.  Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. , 2000, British journal of clinical pharmacology.

[21]  A. Ward,et al.  Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study , 2008, BMC public health.

[22]  Lisa Dolovich,et al.  Promoting Optimal Antibiotic Therapy for Otitis Media Using Commercially Sponsored Evidence-Based Detailing: A Prospective Controlled Trial , 1999 .

[23]  L. Moore,et al.  Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey , 2003, Quality & safety in health care.

[24]  E. Roughead,et al.  Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review , 2009, PloS one.

[25]  E. Berndt,et al.  Demand Effects of Recent Changes in Prescription Drug Promotion , 2003 .

[26]  C. Deangelis,et al.  Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. , 2009, JAMA.

[27]  J. Lexchin,et al.  Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations , 2006, PLoS medicine.

[28]  M. Bowman,et al.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education. , 1988, The Journal of continuing education in the health professions.

[29]  M. Friedman.  There's No Such Thing As a Free Lunch , 1975 .

[30]  J. Cleary,et al.  Impact of Pharmaceutical Sales Representatives on Physician Antibiotic Prescribing , 1992, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[31]  Peter E. Rossi,et al.  Response Modeling with Nonrandom Marketing-Mix Variables , 2004 .

[32]  Andrew T. Ching,et al.  The effects of detailing on prescribing decisions under quality uncertainty , 2009 .

[33]  Troyen A. Brennan,et al.  Physicians and Drug Representatives: Exploring the Dynamics of the Relationship , 2007, Journal of General Internal Medicine.

[34]  A. Burger.  Drugs in Our Society. , 1964 .

[35]  S. Hyman,et al.  Characteristics and Impact of Drug Detailing for Gabapentin , 2007, PLoS medicine.

[36]  D. Weiss,et al.  The Association of Pharmaceutical Company Promotional Spending With Resident Physician Prescribing Behavior , 2005, Academic Psychiatry.

[37]  E. Berndt,et al.  Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants , 2004 .

[38]  Andrew T. Ching,et al.  The Effects of Detailing on Prescribing Decisions under Two-Sided Learning , 2007 .

[39]  W P McKinney,et al.  Pharmaceutical representatives in academic medical centers , 1990, Journal of General Internal Medicine.

[40]  Joel Lexchin,et al.  The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.

[41]  Pierre Azoulay,et al.  Do Pharmaceutical Sales Respond to Scientific Evidence , 2002 .

[42]  A. Figueiras,et al.  Influence of commercial information on prescription quantity in primary care. , 2002, European journal of public health.

[43]  J. Berlin,et al.  When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? , 1996, Academic medicine : journal of the Association of American Medical Colleges.

[44]  P. Masand,et al.  Newly Admitted Psychiatric Patient Prescriptions and Pharmaceutical Sales Visits , 2001, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[45]  M. Chren,et al.  Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. , 1994, JAMA.

[46]  Pradeep K. Chintagunta,et al.  Temporal Differences in the Role of Marketing Communication in New Product Categories , 2005 .

[47]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[48]  R. Pindyck,et al.  Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs , 2000 .

[49]  Stan N. Finkelstein,et al.  Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002 , 2004 .

[50]  P. Mansfield,et al.  General practitioners and pharmaceutical sales representatives: quality improvement research , 2007, Quality and Safety in Health Care.

[51]  J. Orlowski,et al.  The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. , 1992, Chest.

[52]  M. Steinman,et al.  Response to “interactions between pharmaceutical representatives and doctors in training: A thematic review” , 2007, Journal of General Internal Medicine.

[53]  J. Kragstrup,et al.  How conducting a clinical trial affects physicians' guideline adherence and drug preferences. , 2006, JAMA.

[54]  L. Telser,et al.  The Theory of Supply with Applications to the Ethical Pharmaceutical Industry , 1975, The Journal of Law and Economics.

[55]  I. Cockburn,et al.  Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. , 2004, JAMA.

[56]  H. Britt,et al.  The effect of advertising in clinical software on general practitioners’ prescribing behaviour , 2008, The Medical journal of Australia.

[57]  E. R. Peay,et al.  The role of commercial sources in the adoption of a new drug. , 1988, Social science & medicine.

[58]  D. Blumenthal.  Doctors and drug companies. , 2004, The New England journal of medicine.

[59]  Howard Brody,et al.  The Company We Keep: Why Physicians Should Refuse to See Pharmaceutical Representatives , 2005, The Annals of Family Medicine.

[60]  S. Greenfield,et al.  A survey of the advertising of nine new drugs in the general practice literature , 1999, Journal of clinical pharmacy and therapeutics.

[61]  R Dajda.  Drug advertising and prescribing. , 1978, The Journal of the Royal College of General Practitioners.

[62]  H. Acemoğlu,et al.  Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey , 2007, BMC public health.

[63]  E. Hemminki,et al.  The drug industry and medical practice--the case of menopausal hormone therapy in Estonia. , 2004, Social science & medicine.

[64]  Frank Windmeijer,et al.  Pharmaceutical promotion and GP prescription behaviour. , 2006, Health economics.

[65]  D. Kessler,et al.  Demand Effects of Recent Changes in Prescription Drug Promotion , 2003 .

[66]  A. Wazana,et al.  Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.

[67]  Elisabeth Honka,et al.  The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. , 2005, Yale journal of health policy, law, and ethics.

[68]  J. Rizzo,et al.  Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs* , 1999, The Journal of Law and Economics.

[69]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[70]  G. Loewenstein,et al.  Interactions of doctors with the pharmaceutical industry , 2006, Journal of Medical Ethics.

[71]  Joann L. Baril,et al.  Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting? , 2009, Journal of General Internal Medicine.

[72]  K. Leffler,et al.  Persuasion or Information? The Economics of Prescription Drug Advertising , 1981, The Journal of Law and Economics.

[73]  B. McKinstry,et al.  Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey , 2003, Pharmacoepidemiology and drug safety.

[74]  T. Walley,et al.  New drug uptake: qualitative comparison of high and low prescribing GPs' attitudes and approach. , 2003, Family practice.

[75]  Paul Jung,et al.  No free lunch. , 2002, Health affairs.

[76]  J. Vallée.  L'information des médecins généralistes sur le médicament , 2007 .

[77]  T. Walley,et al.  Understanding why GPs see pharmaceutical representatives: a qualitative interview study. , 2003, The British journal of general practice : the journal of the Royal College of General Practitioners.

[78]  Rob Janknegt,et al.  Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives. , 2005, Family practice.

[79]  P. Groenewegen,et al.  Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis , 2007, BMC Health Services Research.

[80]  Füsun F. Gönül,et al.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .